- $1.70bn
- $962.97m
- $1.14m
- 51
- 14
- 14
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.32 | ||
| Price to Tang. Book | 2.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,496.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.63% | ||
| Return on Equity | -19.18% | ||
| Operating Margin | -10067.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 10.36 | 0.19 | 0.2 | 1.14 | 0.8 | 120.67 | -52.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 30th, 2017
- Public Since
- January 25th, 2024
- No. of Shareholders
- 116
- No. of Employees
- 113
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 76,216,855
- Address
- 400 Spectrum Center Drive, Suite 2040, IRVINE, 92618
- Web
- https://www.cgoncology.com/
- Phone
- +1 9492886298
- Auditors
- Ernst & Young LLP
Upcoming Events for CGON
Similar to CGON
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the CG Oncology share price?
As of Today at 19:51 UTC, shares in CG Oncology are trading at $22.37. This share price information is delayed by 15 minutes.
How has the CG Oncology share price performed this year?
Shares in CG Oncology last closed at $22.37 and the price had moved by -38.2% over the past 365 days. In terms of relative price strength the CG Oncology share price has underperformed the S&P500 Index by -42.96% over the past year.
What are the analyst and broker recommendations for CG Oncology?
The overall consensus recommendation for CG Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CG Oncology dividend yield?
CG Oncology does not currently pay a dividend.
Does CG Oncology pay a dividend?
CG Oncology does not currently pay a dividend.
When does CG Oncology next pay dividends?
CG Oncology does not currently pay a dividend.
How do I buy CG Oncology shares?
To buy shares in CG Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CG Oncology?
As of the previous close price of $22.37, shares in CG Oncology had a market capitalisation of $1.70bn.
Where are CG Oncology shares listed?
Here are the trading details for CG Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CGON
What kind of share is CG Oncology?
Based on an overall assessment of its quality, value and momentum CG Oncology is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CG Oncology share price forecast for 2025?
The analyst consensus target price for shares in CG Oncology is $62.38. That is 178.86% above the last closing price of $22.37.
Analysts covering CG Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.78 for the next financial year.
Find out moreWhat is the trend in the CG Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CG Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -35.19%.
As of the last closing price of $22.37, shares in CG Oncology were trading -28.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CG Oncology PE Ratio?
The CG Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CG Oncology?
We do not have data on CG Oncology's directors